

Premarket Approval (PMA) Submissions Workshop

Virtual Event

February 25 – 26, 2021

**Schedule Reflected in Eastern Time*

Feb 25, 2021

- 11:00 – 11:05 am** **Welcome and Introductions**
- 11:05 am – 12:00 pm** **Beginning at the Beginning**
Michael Morton, Michael C. Morton Regulatory Consulting
- When is a De Novo or PMA required
 - PMA: what to expect
 - What are the standards of evidence
 - What are the standards of review
 - Will submission go to panel
 - How much will it cost
 - How long will it take to get approval
- 12:00 – 12:45 pm** **Development of a PMA Submission Strategy**
Dharmesh Patel, FDA
- Product definition
 - Development of testing requirements and strategy
 - Desired patient population
 - Desired claims
 - Early interactions with FDA
 - Planning for product iterations
- 12:45 – 12:50 pm** **Break**
- 12:50 – 1:30 pm** **Mechanics of PMA Quality System Submission Development and Review**
Jhumur Banik, FDA
- Defining data requirements
 - Required elements
 - Presentation of information with clarity
 - Expectations during review
 - Best practices
 - Manufacturing & Quality Systems
 - Case for Quality

Important Notice

The information provided in this course represents the personal opinions of the instructors and does not necessarily represent the opinions of AdvaMed staff. Companies relying on the information do so at their own risk and assume the risk of any subsequent liability that results from relying on the information. The information does not constitute legal advice.



AdvaMed

Advanced Medical Technology Association
Events & Education

1:30 – 2:15 pm

During Submission Review

Jennifer Bolton, Boston Scientific

- Interactions with the FDA
- When/How to expect questions
- Types of letters
- Timelines
- Day 100 meetings
- Labeling review

2:15 – 2:25 pm

Break

2:25 – 3:10 pm

Conditions of Approval Studies

Jennifer Bolton, Boston Scientific

- Criteria and objectives
- Early collaboration with FDA
- Reaching agreement
- Reporting outcomes
- 522 Studies

3:10 – 3:55 pm

Preparation for Advisory Panels

Michael Morton, Michael C. Morton Regulatory Consulting

- When?
- Who are the panel members?
- Why have a panel meeting?
- Preparation for a panel meeting
- What to expect before, during, and after
- Best practices

3:55 – 4:00 pm

Break

4:00 – 4:30 pm

BIMO Audits

Christopher Gioffre, FDA

- The purpose of a BIMO inspection
- When and how a BIMO inspection occurs
- Preventing findings and responding to findings
- Typical and atypical observations – cautionary tales from the field

Important Notice

The information provided in this course represents the personal opinions of the instructors and does not necessarily represent the opinions of AdvaMed staff. Companies relying on the information do so at their own risk and assume the risk of any subsequent liability that results from relying on the information. The information does not constitute legal advice.



AdvaMed

Advanced Medical Technology Association
Events & Education

Feb 26, 2021

11:00 – 11:45 am	Inspection Activity <i>LCDR Kenneth Chen, FDA</i> <ul style="list-style-type: none">• Pre-approval inspections• How to prepare for an inspection
11:45 am – 12:45 pm	Dealing with the Unexpected <i>Quynh Hoang, King & Spalding</i> <ul style="list-style-type: none">• Clinical outcomes• Animal test results• Adverse panel recommendation
12:45 – 12:55 pm	Break
12:55 – 1:40 pm	The Care and Feeding of Approved PMAs <i>Linda Wang, Dexcom</i> <i>Kiley Hubert, Dexcom</i> <ul style="list-style-type: none">• Periodic (“Annual”) Reports• Supplemental Submissions• 30-day notices
1:40 – 2:25 pm	CDRH Ombudsman’s Office – Roles & Responsibilities and the Appeals Process <i>Ken Skodacek, FDA</i>
2:25 – 2:30 pm	Break
2:30 – 3:00 pm	Real World Case Studies <i>Quynh Hoang, King & Spalding</i>
3:00 pm	Closing Remarks and Adjourn

Important Notice

The information provided in this course represents the personal opinions of the instructors and does not necessarily represent the opinions of AdvaMed staff. Companies relying on the information do so at their own risk and assume the risk of any subsequent liability that results from relying on the information. The information does not constitute legal advice.